Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV Infection | Zendy

H. Sindermann | Zendy; Kirsten Engel | Zendy; Christina Fischer | Zendy; W Bommer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV Infection

Author(s) -

H. Sindermann,

Kirsten Engel,

Christina Fischer,

W Bommer

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/425359

Subject(s) - miltefosine , medicine , tolerability , leishmaniasis , human immunodeficiency virus (hiv) , visceral leishmaniasis , immunology , compassionate use , sida , viral disease , clinical trial , adverse effect

Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research